Oryzon Genomics - More data support vafidemstat for aggression
On 3 April 2020, Oryzon reported interim data for the first time from its two Phase IIa trials REIMAGINE-AD and ETHERAL. Both explore the company’s...
303 Views
Oryzon Genomics - More to come after a year of data readouts
As we expected, 2019 was a year of data readouts for epigenetics specialist Oryzon. The company presented new data from the ongoing Phase IIa...
779 Views
Oryzon Genomics - Maturing ALICE trial dataset continues to impress
On 9 December 2019, Oryzon presented more data from the Phase II ALICE trial at the 61st ASH annual meeting in Orlando, Florida. The single-arm,...
1.7k Views
Oryzon Genomics - Interim Phase II CLEPSIDRA results at ESMO
On 28 September 2019, Oryzon presented additional data from its Phase IIa CLEPSIDRA trial with iadademstat, a selective LSD1 inhibitor, at the ESMO...
842 Views
Oryzon Genomics - Phase IIa trial in Alzheimer’s disease initiated
According to the latest news from Oryzon, the first Alzheimer’s disease (AD) patients (3/90) were recruited into the Phase IIa ETHERAL clinical...
57 Views